Metraipolis › archive › dc_11bdd4cb9ded
Targeting VEGF, PARP, and FRα Pathways in Ovarian Cancer: Clinical Advances with Bevacizumab, Rucaparib, and Mirvetuximab Soravtansine — Europe PMC PMID:41827159
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/41827159
- DOI
- 10.3390/jcm15051742
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-05T12:16:17.515Z
- SHA-256 of the archived text
1a827d0f07dcfc9076591662186cd4d218a381220c608446ae83f096a0b803f5- Stable URL of this page
https://metraipolis.com/documento/dc_11bdd4cb9ded
How to cite
Targeting VEGF, PARP, and FRα Pathways in Ovarian Cancer: Clinical Advances with Bevacizumab, Rucaparib, and Mirvetuximab Soravtansine — Europe PMC PMID:41827159 — Europe PMC (en), https://europepmc.org/article/MED/41827159 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_11bdd4cb9ded (Metraipolis archive dc_11bdd4cb9ded, sha256 1a827d0f07dcfc9076591662186cd4d218a381220c608446ae83f096a0b803f5)
BibTeX
@misc{dc11bdd4cb9ded,
title = {Targeting VEGF, PARP, and FRα Pathways in Ovarian Cancer: Clinical Advances with Bevacizumab, Rucaparib, and Mirvetuximab Soravtansine — Europe PMC PMID:41827159},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/41827159},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_11bdd4cb9ded; sha256 1a827d0f07dcfc9076591662186cd4d218a381220c608446ae83f096a0b803f5},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41827159. Agents can read the archived copy with the MCP tool read_document.